Page last updated: 2024-11-05

trimebutine and Sepsis

trimebutine has been researched along with Sepsis in 1 studies

Trimebutine: Proposed spasmolytic with possible local anesthetic action used in gastrointestinal disorders.

Sepsis: Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Ogawa, N1
Nakajima, S1
Tamada, K1
Yokoue, N1
Tachibana, H1
Okazawa, M1
Oyama, T1
Abe, H1
Yamazaki, H1
Yoshimori, A1
Sato, A1
Kamiya, T1
Yokomizo, T1
Uchiumi, F1
Abe, T1
Tanuma, SI1

Other Studies

1 other study available for trimebutine and Sepsis

ArticleYear
Trimebutine suppresses Toll-like receptor 2/4/7/8/9 signaling pathways in macrophages.
    Archives of biochemistry and biophysics, 2021, 10-30, Volume: 711

    Topics: Animals; Anti-Inflammatory Agents; Chemokines; Female; Interleukin-6; Lipopolysaccharides; Macrophag

2021